Member Info for Krone

On the assumption that Sareum are awarded a grant how long would it realistically take to work up a Robust partnership agreement with X Pharma and to commence trials in the Covid context. Sareum does not have the resources financial or otherwise to run trials themselves, at a pace required in the current circumstances. As others have suggested this must all point to a partnership with big pharma. It would be reasonable to suppose that any RNS will be held until then.

HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19 https://immunology.sciencemag.org/content/5/47/eabc5367…
"the use of JAK inhibitors targeting ... cytokines with JAK-dependent signaling is one way to restrain the excessive level of cytokine signaling"
Sareum $SAR.L #TYK2https://twitter.com/Sareumplc/status/1260124940965158915?https://immunology.sciencemag.org/content/5/47/eabc5367

Hi ghjones1 - thanks for the interesting post.

Thanks workinginpharma for the original post and Fadec, RMM and Stoney for follow up. Agree that we need Sareum to comment and actively use this and similar opportunities to highlight the massive potential of Sareum's assets in the Covid19 context.

Hi workinginpharma, + Fadec, Thoth, RMM et al,
Re: https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30127-2/fulltext
How close a proxy is Anakinra to Sar's TYK2/JAK1 assets?
Is IL-1ß referred to in the paper the same as per slide 9 of Sar's latest presentation? http://www.sareum.com/files/4715/8801/5577/TimMitchell-Sareum_BioTrinity20.pdf
In other words, does the Anakinra paper relate directly to Sareum?

Just listening to todays BBC Corona Show highlights the absolutely mind bogglingly massive potential opportunity for Sareum if we can pull off the SDC1801 trial. This is against a backdrop where very many other trials are being paused as reported by Endpoints https://endpts.com/wp-content/uploads/pdfs/aeeb61e3fb9d7cb6bd88dcb29bc11839.pdf
Realising the full financial value of the asset will take skilful negotiation and just hoping that Stephen Parker et al can bring this home safely!

https://api.nationalgeographic.com/distribution/public/amp/science/2020/05/how-quieting-cytokine-storms-could-be-key-to-treating-severe-cvd

Yet another paper on cytokines storms.

Hi Fadec, many thanks for sharing your thoughts. In essence, from Sareum’s perspective we need assurance that Stephen Parker has stepped up pressure on Sierra via ICR. IMO he certainly gave the impression at the AGM that he was on the case but as you say this has been dragging on for nearly a year with no substantive news. Of course the imminent data readout may change everything.

Hi Aber, absolutely and furthermore the CRT/ICR won't want and can't afford the significant reputational damage and negative PR from being associated with an outfit run by NG.

An explanation of cytokine storms in layman's terms: https://www.bbc.com/future/article/20200505-cytokine-storms-when-the-body-attacks-itself

Novartis, Incyte will take Jakafi into 2nd trial for COVID-19 patients on ventilators
by Kyle Blankenship | May 5, 2020 10:40am
Jakafi
Novartis and Incyte announced their first Jakafi study in COVID-19 back in April. (Novartis)
Share
Facebook
Twitter
LinkedIn
Email
Print
Novartis and Incyte have already pitted their blockbuster JAK inhibitor Jakafi against COVID-19 as a possible treatment for a severe respiratory immune reaction. Now, seeing promise in another category of coronavirus-afflicted patients, the partners will take Jakafi into a second late-stage trial.

The partners plan to test Jakafi in a second phase 3 trial for COVID-19 patients with acute respiratory distress syndrome (ARDS), the drugmaker announced alongside first-quarter earnings Tuesday.

The U.S. trial will evaluate Jakafi's safety and efficacy over standard of care in ARDS patients who've needed ventilators.
A panel of CATO SMS experts will review the key issues contained in the emerging Agency Guidance and offer thoughts on what changes and options for sponsors may be seen in the coming months.
Incyte and partner Novartis announced in early April that they would roll Jakafi—also known as ruxolitinib—into a phase 3 study evaluating its ability to treat cytokine storm, an immune system overreaction that can cause severe respiratory complications.
RELATED: Novartis, Incyte set to roll JAK inhibitor Jakafi into COVID-19 clinical trial
The blinded, double-arm study, dubbed Ruxcovid, will evaluate a combination of Jakafi alongside standard-of-care therapy to treat COVID-19 patients with pneumonia, the partners said.
Even with two global clinical studies of Jakafi underway, Incyte said the partners have enough supply of the drug to stave off shortages moving ahead.
"Incyte’s manufacturing processes are proceeding as usual, with increased manufacturing efforts for (Jakafi) in place to respond to the COVID-19 pandemic and study requests," Incyte said in a release.
Novartis and Incyte immediately rolled out a compassionate use program for Jakafi pending local regulations. Jakafi, which the FDA initially approved to treat myelofibrosis in 2011, is also approved to treat polycythemia vera and chronic graft-versus-host disease.
In the first quarter, Jakafi posted global revenues of $459 million, Incyte said.
RELATED: Lilly partners with NIH to test Olumiant in patients hospitalized with COVID-19
Incyte partner Eli Lilly has also taken rheumatoid arthritis med Olumiant into COVID-19 trials in conjunction with the National Institute of Allergy and Infectious Diseases.
The Olumiant trial stemmed from an analysis by Benevolent AI, a U.K. artificial intelligence group, that identified the drug as a possible COVID-19 treatment not only for its anti-inflammatory effects, but also an antiviral effect, Lilly Bio-Medicines president Patrik Jonsson told FiercePharma.

"Now, seeing promise in another category of coronavirus-afflicted patients, the partners will take [JAK inhibitor] Jakafi into a 2nd late-stage trial."
https://twitter.com/Sareumplc/status/1257948584777039872?s=20

https://twitter.com/sareumplc/status/1257649705930166272?s=21

Hi RMM - absolutely and hopefully Stephen Parker is breathing down NG's neck via CRT. I am reminded of Tim's comment months ago to the effect that there is 'every chance' that NG will identify non-dilutive funding i.e. on-licence 737. If as Thoth suggests, 737 has any potential efficacy in respect of Covid19 no doubt NG will be jostling for position.

Hi Potnak, but as Thoth has conjectured if NG goes for 2b with 737 we’ll get milestones and won’t need to raise. Either way it’s looking like a good summer, lock down or not.

?Hi Fadec - Recent AZN paper - Discovery of (2R)-N-[3-[2-[(3-Methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a Potent and Selective Janus Kinase 1 Inhibitor https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01392#.Xq7lHH_Iz3Q.twitter?

The conference call and slides detailed below provides a good outline of the process, protocols etc which presumably will apply to any Covid19 related trial of SDC-1801
https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20200429_9

Hi RMM - again, many thanks for your post. Look to your further thoughts in due course.
Re Covid19 - For comparison purposes it might be helpful to look at another small company BerGenBio which has just received grant funding to progress a fast tracked trial.
https://www.bergenbio.com/bergenbios-bemcentinib-selected-to-be-fast-tracked-as-potential-treatment-for-covid-19-through-new-national-uk-government-clinical-trial-initiative/

I guess £800m for each Tyk2 would be about 50p plus CHK1 + Aurora....rounded up to a quid!